Navigator 1.5 Accuracy Study

In Clinic Evaluation of the FreeStyle Navigator® Continuous Glucose Monitoring System Version 1.5

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01076218

Acronym

FSNQS

Enrollment

Registered

2010-02-26

Start date

2008-04-30

Completion date

2008-07-31

Last updated

2024-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Continuous Glucose Monitoring, Accuracy, Continuous Glucose Error-Grid Analysis

Brief summary

The purpose of the study is to confirm that the accuracy and safety of Version 1.5 of the FreeStyle Navigator Continuous Glucose Monitoring System are not impacted by the updates to the system algorithm and minor changes to the user interface and sensor delivery unit, such as adhesive sterilization method. It is anticipated that information collected will be submitted as a supplement to Premarket Approval Application (P050020) to the US Food and Drug Administration for approval to market this version of the system.

Interventions

DEVICEFreeStyle Navigator Continuous Glucose Monitoring System Version 1.5

This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* History consistent with Type 1 diabetes for at least 2 years prior to enrollment; * For at least 6 months prior to enrollment, insulin pump user or multiple daily insulin injections; * At least 18 years of age; * Available and capable of following the protocol instructions provided by the healthcare professional; * Signed and dated Informed Consent form.

Exclusion criteria

* Pregnancy; * Type 2, gestational, or secondary diabetes; * Known allergy to medical grade adhesives or skin disinfectant; * Skin abnormalities at the insertion sites that would confound the assessment of the effect of the device on the skin; * Blood donation within 6 weeks prior to beginning study activities; * Within past 6 months, severe hypoglycemic episode(s) resulting in hospitalization or loss of consciousness; * Active myocardial ischemia; * Previous history of stroke; * Any other concomitant medical condition that in the opinion of the principal investigator would likely affect the evaluation of device performance and/or safety; * Current participation in another clinical trial.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026